Warning! GuruFocus has detected 2 Severe warning signs with CALT. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for CALT (Calliditas Therapeutics AB) from 2020 to May 16 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Calliditas Therapeutics AB stock (CALT) PE ratio as of May 16 2021 is 0. More Details
Calliditas Therapeutics AB PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Calliditas Therapeutics AB PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Kungsbron 1, C8, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.